Croban Invests $715,000 in Pfizer Inc. (NYSE:PFE)

Croban acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 28,213 shares of the biopharmaceutical company's stock, valued at approximately $715,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $27,000. Gould Capital LLC grew its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the period. North Capital Inc. acquired a new position in Pfizer during the first quarter worth $28,000. Bernard Wealth Management Corp. bought a new position in shares of Pfizer in the fourth quarter valued at $30,000. Finally, Curio Wealth LLC bought a new stake in shares of Pfizer during the fourth quarter worth about $32,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on PFE shares. Morgan Stanley boosted their target price on shares of Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. BMO Capital Markets decreased their price objective on shares of Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Citigroup boosted their target price on Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Redburn Atlantic cut their target price on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. Finally, Jefferies Financial Group boosted their target price on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $28.55.

Pfizer Trading Down 0.5%

Shares of NYSE:PFE traded down $0.13 on Friday, reaching $25.65. 34,838,317 shares of the company traded hands, compared to its average volume of 41,793,724. The business's 50-day simple moving average is $23.86 and its 200 day simple moving average is $24.81. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The stock has a market capitalization of $145.83 billion, a P/E ratio of 18.59, a price-to-earnings-growth ratio of 0.94 and a beta of 0.58. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period last year, the business posted $0.82 earnings per share. Pfizer's quarterly revenue was down 7.8% compared to the same quarter last year. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.71%. Pfizer's payout ratio is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.